American Society of Clinical Oncology (ASCO) Annual Meeting | Chicago | 2026

Roche highlights giredestrant’s evolving role in breast cancer treatment

Roche continues to build on its recent data, reinforcing giredestrant’s potential to reshape the treatment paradigm in early breast cancer and expand its role across advanced disease.

What is the mechanism of action of giredestrant?

Giredestrant is an investigational, oral, selective oestrogen receptor degrader (SERD) being developed for ER‑positive, HER2‑negative breast cancer across both early and advanced settings. This subtype accounts for about 70% of all breast cancers, and most patients are diagnosed at an early stage.

Also read: Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Results from three Phase III trials will underpin future discussions on how giredestrant may become a key endocrine therapy option across multiple stages of disease:

lidERA Breast Cancer

Following the previously reported reduction in the risk of invasive disease recurrence or death, new lidERA data will continue to inform how giredestrant performs in both premenopausal and postmenopausal patients with early breast cancer. These findings will support ongoing regulatory and clinical discussions with the US FDA.

persevERA Breast Cancer

The persevERA primary results will remain important for understanding giredestrant in combination with palbociclib as a first‑line option for locally advanced or metastatic endocrine‑sensitive disease. Although the primary endpoint is not met, the numerical improvement in progression‑free survival suggests that giredestrant retains activity in the first‑line setting and may guide future study designs.

Also read: Top 10 Pharmaceutical Companies by Revenue 2025

evERA Breast Cancer

Updated post‑progression analyses from evERA will continue to highlight the sustained clinical benefit of giredestrant plus everolimus after prior CDK4/6 inhibitor therapy. These data support the recently accepted New Drug Application with the US FDA and will shape how the regimen is positioned in later‑line treatment strategies.